<DOC>
	<DOCNO>NCT00003896</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine paclitaxel , cisplatin , liposomal doxorubicin treat woman undergone surgery stage III ovarian cancer , fallopian tube cancer , primary peritoneal cancer .</brief_summary>
	<brief_title>S9912 Combination Chemo Stage III Ovarian Cancer ,</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy intraperitoneal ( IP ) cisplatin , IP IV paclitaxel , IV doxorubicin HCl liposome , term progression-free survival overall survival , patient optimally debulked stage III ovarian epithelial , fallopian tube , primary peritoneal cancer . - Determine feasibility toxic effect associate regimen patient . OUTLINE : This multicenter study . Patients receive paclitaxel IV 3 hour day 1 , intraperitoneal ( IP ) cisplatin 30-60 minute day 2 , IP paclitaxel 30-60 minute day 8 , doxorubicin HCl liposome IV 1 hour day 8 . Patients able tolerate IP infusion receive paclitaxel IV cisplatin IV day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 62 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III ovarian epithelial , fallopian tube , primary peritoneal carcinoma Tumor involve one ovaries microscopically confirm peritoneal metastasis outside pelvis and/or regional lymph node metastasis No tumor borderline low malignant potential Mixed Mullerian tumor allow Must optimal disease define residual lesion resection residual disease single lesion measure great 1 cm diameter Must undergone stag exploratory laparotomy tumor debulking within past 70 day PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 01 Life expectancy : Not specify Hematopoietic : Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 2 time ULN Renal : Creatinine clearance ≥ 50 mL/min Cardiovascular : No congestive heart failure No cardiac arrhythmia No myocardial infarction unstable angina within past 6 month Patients history myocardial disease must ischemia pathologic arrhythmia must ejection fraction &gt; 50 % MUGA Other : Not pregnant nursing Fertile patient must use effective contraception No active uncontrolled infection No concurrent fever No grade 2 great sensory neuropathy No severe gastrointestinal symptom ( i.e. , partial obstruction ) and/or bleeding , diarrhea , abdominal tenderness suggestive peritoneal irritation infection No erythema tenderness abdominal incision port site suggestive underlying infection No malignancy within past five year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy ovarian cancer Chemotherapy : No prior chemotherapy ovarian cancer Endocrine therapy : Not specify Radiotherapy : No prior pelvic radiotherapy ovarian cancer Surgery : See Disease Characteristics Recovered reversible surgeryrelated toxic effect Other : No concurrent antitumor treatment No concurrent antibiotic infection undetermined etiology</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>